2019-09-01
2020-10-30
2022-08-31
302
NCT05547074
Zhejiang University
Zhejiang University
OBSERVATIONAL
A New Prognostic Score Model for Pancreatic Ductal Adenocarcinoma
The AJCC TNM staging system is the prevailing method in prognostic evaluation of pancreatic ductal adenocarcinoma (PDAC) at present , but it did not include factors such as the tumor immune microenvironment that are known to exert a profound impact on patients'clinical outcome. This study was aimed to develop a comprehensive and effective prognostic score model to predict prognosis and guide clinical management for postoperative PDAC patients.
N/A
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
| Study Registration Dates | Results Reporting Dates | Study Record Updates |
|---|---|---|
2022-09-15 | N/A | 2022-09-20 |
2022-09-15 | N/A | 2022-09-22 |
2022-09-21 | N/A | 2022-09 |
This section provides details of the study plan, including how the study is designed and what the study is measuring.
Primary Purpose:
N/A
Allocation:
N/A
Interventional Model:
N/A
Masking:
N/A
Arms and Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
| : The training cohort To develop the prognostic model, 302 cases of postoperative PDAC were included in the final analysis and divided into the training and validation cohort by stratified sampling with 7:3 ratio (The training cohort: n=212; The validation cohort: n=90). | PROCEDURE: pancreatic cancer surgery
|
| : The validation cohort To develop the prognostic model, 302 cases of postoperative PDAC were included in the final analysis and divided into the training and validation cohort by stratified sampling with 7:3 ratio (The training cohort: n=212; The validation cohort: n=90). | PROCEDURE: pancreatic cancer surgery
|
| Primary Outcome Measures | Measure Description | Time Frame |
|---|---|---|
| overall survival | the number of months from the date of surgery to the date of the last follow-up visit or time of death. | after pancreatic cancer surgery until october 31, 2020 |
| Secondary Outcome Measures | Measure Description | Time Frame |
|---|---|---|
| disease-free survival disease-free survival disease-free survival disease-free survival | the number of months from the date of surgery to the date of first confirmable recurrence or death | after pancreatic cancer surgery until october 31, 2020 |
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.
Ages Eligible for Study:
ALL
Sexes Eligible for Study:
Accepts Healthy Volunteers:
This is where you will find people and organizations involved with this study.
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
No publications available
NPCF was founded on May 29, 2009 and is a 501(c)(3) organization. All donations are tax deductible.
The information and services provided by the National Pancreatic Cancer Foundation are for informational purposes only. The information and services are not intended to be substitutes for professional medical advice, diagnosis or treatment. The National Pancreatic Cancer Foundation does not recommend nor endorse any specific physicians, products or treatments even though they may be mentioned on this site.
Copyright © 2024 – National Pancreatic Cancer Foundation | All Rights Reserved
